A 16-year-old girl born from a nonconsanguineous marriage presented to the dermatology out-patient department with innumerable hyperpigmented macules predominantly over the photoexposed parts of her body involving the face, neck, chest, back, of forearms, hands, and legs with a history of photosensitivity and photophobia (Figure 1). These were interspersed with multiple depigmented macules over her arms and legs since, she was three years old. She also had a small pigmented mass involving the left eye present for the last 3 months. She had a family history of similar cutaneous lesions in her elder sister. There was no history of hearing loss, seizures, spasticity, or cognitive impairment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Metastatic conjunctival melanoma: a multicentre international study.
Br J Ophthalmol
December 2024
Orbit and Oncology, Calle Ophthalmic and Orbit Center, Bogotá, Colombia.
Background: To reveal clinical findings related to metastatic conjunctival melanoma.
Methods: 10 ophthalmic oncology centres (9 countries and 4 continents) shared data to create a large clinical case series. The main outcome measures were the incidence and cumulative risk of systemic metastasis, study mortality rates and Kaplan-Meier patient mortality after developing conjunctival melanoma metastasis.
[TREATMENT UPDATES IN OCULAR ONCOLOGY].
Harefuah
December 2024
Ophthalmology Department, Shaare Tzedek Medical Center.
Article Synopsis
- Malignant tumors of the eye, while rare, significantly impact patients' lives and vision, with retinoblastoma in children and uveal melanoma in adults being the most common types.
- Managing these tumors poses challenges, such as controlling intraocular spread which affects survival rates, and dealing with eyelid tumors that might invade ocular tissue, complicating surgical removal.
- Recent advancements in treatment over the past decade aim to enhance patient survival and preserve vision, including emerging therapies for both common tumors and rare types like conjunctival melanoma.
Correction: Butt et al. Conjunctival Melanoma: A Clinical Review and Update. 2024, 3121.
Cancers (Basel)
November 2024
National Specialist Ophthalmic Pathology Service, Liverpool Clinical Laboratories, Liverpool University Hospitals NHS Foundation Trust, Liverpool L7 8YE, UK.
The authors would like to include the following acknowledgment in the publication [...
View Article and Find Full Text PDFConjunctival Melanoma: A Clinical Review and Update.
Cancers (Basel)
September 2024
National Specialist Ophthalmic Pathology Service, Liverpool Clinical Laboratories, Liverpool University Hospitals NHS Foundation Trust, Liverpool L7 8YE, UK.
Conjunctival melanoma (Co-M) is an aggressive, invasive eye and eyelid cancer. Its global incidence of ~1 in a million is increasing at a rate ratio of ~1.4, but this rises sharply in over 65-year-olds.
View Article and Find Full Text PDFUnilateral amelanotic conjunctival malignant melanoma: a case report.
J Med Case Rep
September 2024
Department of Clinical Pathology, Sahlgrenska University Hospital, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Article Synopsis
- Cutaneous malignant melanomas are rarely found in the eye, particularly as conjunctival malignant melanomas, which are even less common and can be difficult to diagnose, especially in their amelanotic form.
- The article presents two cases of Swedish Caucasian women, one aged 81 and the other 50, who were diagnosed with amelanotic malignant melanoma in the conjunctiva, with varying treatment outcomes; the first underwent orbital exenteration while the second was treated with brachytherapy and local chemotherapy, preserving her eye.
- It is crucial for healthcare providers to suspect amelanotic malignant melanoma when tumors are present in the eye or eyelids to facilitate prompt treatment and reduce the risk of metastasis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!